ArticleChinese herbal medicines2026
Retrospective cohort study on Shufeng Jiedu granules for SARS-CoV-2 infection: Real-world evidence from multicenter outpatient clinics in a predominantly caucasian population.
Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Due to the lack of clinical evidence on the effectiveness and safety of Shufeng Jiedu (SFJD) Granules in Europe, it is unclear if SFJD can effectively and safely be used as an adjunct treatment for mild SARS-CoV-2 infection in a predominantly Caucasian outpatient population in Germany. Therefore, we conducted a retrospective cohort study to evaluate the real-world effectiveness and safety of SFJD compared to standard symptomatic care Methods: This retrospective cohort study included adult patients (≥ 18 years) with mild SARS-CoV-2 infection symptoms treated between October 2021 and March 2023 across four outpatient clinics in Hamburg, Germany. Patients were allocated to either the SFJD group or a control group receiving standard symptomatic care. Clinical data, including symptom duration, intensity [measured by Visual Analogue Scale (VAS)], and adverse events, were analyzed. The primary endpoint was the time to total symptom alleviation (TTSA), defined as the first 24-hour period with all index symptoms rated VAS ≤ 1 and no temperature ≥ 37.0 °C. Secondary outcomes included symptom-specific duration and intensity. Data were verified by propensity score matching (PSM). Results: A total of 81 patients met inclusion criteria, with 38 patients assigned to the SFJD group and 43 patients assigned to the control group. Baseline characteristics were comparable between groups. The SFJD group showed a statistically significant different Time to Total Symptom Alleviation (TTSA) compared to controls [(5.76 ± 3.74) d and (11.50 ± 7.45) d, difference of 5.74 d, Conclusion: SFJD Granules demonstrated beneficial effects in reducing the duration and intensity of mild SARS-CoV-2 infection symptoms in a real-world outpatient setting, without significant safety concerns. These findings support the potential of SFJD as an adjunctive therapy for early-stage COVID-19, especially in populations outside of East Asia. Prospective randomized trials are warranted to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.